Roger Salengro Hospital - Lille University Hospital
Lille, 59037, France
NCT Number: NCT07360548
Pituitary adenomas (PAs) are common benign tumors, but their potential for tumor aggression and hormone secretion make them serious tumors. In particular, patients with secreting tumors [prolactinomas (prolactin secretion), acromegaly (growth hormone), Cushing's disease (ACTH), thyrotropic adenomas (TSH)] have increased morbidity and mortality. They may be small and/or undetectable by magnetic resonance imaging (MRI), the current gold standard for morphological evaluation of pituitary lesions. The diagnosis of recurrence in a patient who has already undergone surgery also raises the problem of distinguishing between a lesion and postoperative remodeling. The detection of these tumors therefore represents a significant challenge in guiding therapeutic management.Nuclear medicine could solve this challenge, particularly radiopharmaceuticals (MRPs) used in PET (positron emission tomography) combined with CT scans. A few studies have evaluated MRPs in the context of APs, with those targeting amino acid metabolism proving to be the most promising, particularly carbon-11-labeled methionine (11C-MET). In retrospective studies only, 11C-MET PET has shown excellent performance in all situations where MRI fails (detection rate >80%), but the extremely short half-life of 11C requires heavy infrastructure, limiting its access in routine clinical practice.18Fluoroethyl-Tyrosine (18FET) is also a PET MRP targeting amino acid metabolism used in France in neuro-oncology with performance equivalent to 11C-MET, and which has the advantage of being available daily in all nuclear medicine centers.
The performance of 18FET in APs is almost unknown, with only two retrospective studies recently published, including 22 patients with Cushing's disease on the one hand and 17 patients with prolactinoma on the other: The detection rates were particularly interesting (82% and 100% respectively), but it is imperative to confirm these data prospectively and to evaluate the performance of this MRP in other functional types, which is therefore the purpose of this study.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 2
Lille, 59037, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The protocol consists of a single arm involving the administration of the radiopharmaceutical 18FET (IASOglio).
This will be administered once during the study, directly intravenously with an activity of 200 +/- 15MBq, as recommended by the European EANM/EANO/RANO guidelines and used in retrospective studies investigating the contribution of 18FET in AP. Included patients will have fasted for at least 4 hours beforehand. PET image acquisition will begin as soon as the radiopharmaceutical is injected.
Other names: IASOglio 2 GBq/mL : Marketing authorization number : 34009 550 105 1 7 (15mL) / 34009 550 105 2 4 (25 mL)
Time frame: 2 months +/- 2 months
Frequency of patients for whom PET would be useful among patients with a positive 18FET PET result.The gold standard will be defined by the pathological examination of the surgical specimen in the case of surgery, or by the possibility of stopping or gradually reducing medical treatment while maintaining normalized hormone secretion in the case of radiotherapy.
Time frame: 2 months +/- 2 months
Frequency of patients with positive 18FET PET scans.
Time frame: 2 months +/- 2 months
SUVmax (g/mL) based on the result of the 18FET PET scan (patients negative on the 18FET PET scan, patients positive on the 18FET PET scan and successfully treated, and patients positive on the 18FET PET scan but not treated or treatment failure).
Time frame: 2 months +/- 2 months
Based on the result of the 18FET PET scan (patients negative on the 18FET PET scan, patients positive on the 18FET PET scan and successfully treated, and patients positive on the 18FET PET scan but not treated or treatment failure).
Time frame: 2 months +/- 2 months
Kinetic parameters (time to peak in minutes) based on the result of the 18FET PET scan (patients negative on the 18FET PET scan, patients positive on the 18FET PET scan and successfully treated, and patients positive on the 18FET PET scan but not treated or treatment failure).
Time frame: 2 months +/- 2 months
Concordance will be measured by the Krippendorf coefficient.
Time frame: 1 year +/- 2 months
Frequency of patients undergoing surgery and frequency of patients undergoing radiation therapy among patients who tested positive on 18FET PET scans.
Contact information is provided by the study sponsor or research team.
University Hospital, Lille
Other
18F-fluoro-ethyl-tyrosine (18FET) PET for Difficult Clinical Situations in Functional Pituitary Adenoma. A Prospective, Single Arm, Single Center Study
Acronym: FET-PIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.